XWPharma Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 21

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 9

XWPharma General Information

Description

Developer of novel therapeutics intended to treat sleep, neuropsych, and other underserved central nervous system disorders. The company specializes in drug discovery and vaccine development for neurological and neuropsychiatric disorders, enabling patients to overcome insomnia and other sleep disorders and lead healthy lives.

Contact Information

Website
www.xwpharma.com
Formerly Known As
XW Laboratories
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3 Lagoon Drive
  • Suite 160
  • Redwood City, CA 94065
  • United States
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Life Sciences
Corporate Office
  • 3 Lagoon Drive
  • Suite 160
  • Redwood City, CA 94065
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

XWPharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Secondary Transaction - Private 06-Jun-2023 Completed Clinical Trials - General
4. Later Stage VC (Series C) 17-Sep-2020 Completed Clinical Trials - General
3. Early Stage VC (Series B) 20-Sep-2017 Completed Clinical Trials - General
2. Secondary Transaction - Private 18-May-2017 $5.5M Completed Clinical Trials - General
1. Early Stage VC (Series A) 01-Sep-2014 $5.5M $5.5M Completed Clinical Trials - General
To view XWPharma’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

XWPharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of novel therapeutics intended to treat sleep, neuropsych, and other underserved central nervous system disord
Drug Discovery
Redwood City, CA
21 As of 2025

Plymouth Meeting, PA
 

Austin, TX
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

XWPharma Competitors (76)

One of XWPharma’s 76 competitors is Harmony Biosciences, a Formerly VC-backed company based in Plymouth Meeting, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Harmony Biosciences Formerly VC-backed Plymouth Meeting, PA
Cassava Sciences Formerly VC-backed Austin, TX
CuraSen Venture Capital-Backed San Carlos, CA
Iconic Therapeutics Formerly VC-backed South San Francisco, CA
NeuroNascent Venture Capital-Backed Clarksville, MD
You’re viewing 5 of 76 competitors. Get the full list »

XWPharma Patents

  • 191

    Total Documents Applications and Grants

  • Total Patents Families

  • 143

    Granted

  • 43

    Pending

  • Expiring in next 12 mo

XWPharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20250041258-A1 Pharmaceutical compositions of a gamma-hydroxybutyric acid derivative Pending 31-Jul-2023
US-20250041425-A1 Excipient granulations Pending 31-Jul-2023
US-20240092727-A1 Crystalline 4-((l-valyl)oxy)butanoic acid Pending 06-Sep-2022
AU-2023338669-A1 Crystalline 4-((l-valyl)oxy)butanoic acid Pending 06-Sep-2022
US-20230098084-A1 Pharmaceutical compositions and oral dosage forms of ketamine derivatives Active 13-Aug-2021 A61K31/135
To view XWPharma’s complete patent history, request access »

XWPharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

XWPharma Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
CDIB Capital Group Venture Capital Minority
Orient Hontai Capital PE/Buyout Minority
Panacea Venture Venture Capital Minority
Trinity Innovation Fund Venture Capital Minority
Woori Venture Partners Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

XWPharma FAQs

  • When was XWPharma founded?

    XWPharma was founded in 2014.

  • Where is XWPharma headquartered?

    XWPharma is headquartered in Redwood City, CA.

  • What is the size of XWPharma?

    XWPharma has 21 total employees.

  • What industry is XWPharma in?

    XWPharma’s primary industry is Drug Discovery.

  • Is XWPharma a private or public company?

    XWPharma is a Private company.

  • What is XWPharma’s current revenue?

    The current revenue for XWPharma is .

  • How much funding has XWPharma raised over time?

    XWPharma has raised $63M.

  • Who are XWPharma’s investors?

    CDIB Capital Group, Orient Hontai Capital, Panacea Venture, Trinity Innovation Fund, and Woori Venture Partners are 5 of 9 investors who have invested in XWPharma.

  • Who are XWPharma’s competitors?

    Harmony Biosciences, Cassava Sciences, CuraSen, Iconic Therapeutics, and NeuroNascent are some of the 76 competitors of XWPharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »